2281), a competitive inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1), has been used in the clinical treatment of ovarian cancer with BRCA1/2 gene mutations (58, 59). Here, PARP1 is linked to ovarian carcinoma.